Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
If you have tried to buy weight loss injections in Pakistan, you will recognise the pattern. A price quoted last month is higher this month. A supplier who had stock has none. A course started confidently stalls at week ten.
None of this is random, and none of it is your supplier being difficult. The causes are structural, and understanding them helps you plan rather than hope.
Cause one: peptides are hard to make
Semaglutide, tirzepatide, liraglutide and dulaglutide are peptides, meaning chains of amino acids. They are manufactured biologically rather than by conventional chemistry.
That distinction matters enormously for supply.
Peptide manufacturing requires specialised facilities, specialised expertise and lengthy validation. You cannot simply increase output when demand rises. Building new capacity takes years, and every unit of new capacity has to be qualified and approved before it produces anything sellable.
When weight loss demand arrived, existing capacity was already committed to diabetes supply. The shortfall was immediate and could not be fixed quickly.
Cause two: the pens are also a bottleneck
Less obvious and genuinely significant.
These drugs are supplied in pre-filled injector pens, which are precision devices. Manufacturing them is a separate constraint from manufacturing the drug.
At various points the limiting factor has been pen assembly capacity rather than drug supply. Having the molecule is not the same as having a sellable product.
Cause three: demand keeps expanding
Each new indication widens the market.
These started as diabetes drugs. Then weight management. Then cardiovascular risk reduction following SELECT. Sleep apnea, fatty liver and other indications continue to be studied.
Meanwhile tirzepatide demonstrated 20.9 percent average weight reduction in SURMOUNT-1, which drives demand independently of any formal indication.
Every expansion adds patients to a supply that was already short.
Cause four: unofficial markets are served last
This is the part specific to Pakistan, and it explains why local availability is worse than global reports suggest.
During a shortage, manufacturers prioritise regulated markets where they have registration, contractual obligations and regulatory scrutiny. Diabetes patients on established treatment are prioritised over new weight loss demand.
Pakistan has none of that standing, because no GLP-1 medication is registered here. There is no local registration, no supply agreement and no obligation to serve this market at all.
Everything arriving here comes through personal import, informal medical supply and resale from other markets. That is the last claim on constrained supply, and it is the first to disappear.
Cause five: the exchange rate
Every unit is bought in dollars or euros before it reaches Pakistan. Rupee weakness feeds directly into local pricing within weeks.
This operates independently of the shortage. Even in a well-supplied year, currency movement alone would push prices up.
Combine currency pressure with scarcity pricing and the swings become large.
Cause six: chain length
The more intermediaries between manufacturer and you, the more margin accumulates and the more fragile the chain.
An informal import route may involve a purchaser abroad, a courier, a local distributor and a reseller. Each adds cost. Each is a point where the chain can break.
Longer chains also make authenticity harder to establish, which connects directly to the next problem.
What the shortage produces
Scarcity has a predictable consequence.
The World Health Organization estimates at least 1 in 10 medical products in low- and middle-income countries is substandard or falsified, and notes these are often sold online and through informal markets.
Where legal supply cannot meet demand, counterfeit supply fills the gap. Falsified semaglutide pens have been found in multiple countries, some containing insulin, some containing nothing.
Shortage and counterfeiting are not separate problems. The first causes the second.
What this means for planning a course
The practical consequences are worth stating directly.
Do not assume continuity. A supplier with stock today may have none in eight weeks.
Budget for price increases, not a fixed monthly figure.
Understand the restart cost. A broken course means appetite returns, weight regain follows, and re-escalating from a lower dose is usually necessary because side-effect tolerance fades. You pay again for weeks already bought.
Treat unusually cheap offers with suspicion rather than relief.
Do not stockpile improperly. Buying several months ahead to hedge against shortage only helps if refrigeration is genuinely maintained throughout.
What might change this
Two developments matter.
Small-molecule oral drugs. Orforglipron, approved in April 2026, is a small molecule rather than a peptide. It can be manufactured by conventional pharmaceutical chemistry, in facilities that already exist in large numbers including across South Asia, and it needs no cold chain. That sidesteps both bottlenecks at once. It is not available in Pakistan.
Patent expiry. As patents lapse in various markets, generic manufacture becomes possible, which historically brings prices down substantially. Timing varies by country and by molecule.
Neither is an immediate solution for someone trying to start treatment this month.
What is stable now
The reason locally registered options exist is precisely this instability.
A needle-free GLP-1 option that is registered and manufactured for this market does not depend on an import shipment arriving, does not require a cold chain that can fail, and does not carry the authenticity problem that unregistered imports do. METASLIM™ is a physician-reviewed sublingual supplement rather than a pharmaceutical GLP-1 receptor agonist, so SURMOUNT-1 figures do not describe it and nobody should imply otherwise.
What it offers against this backdrop is predictability, which in a market defined by supply failure is not a small thing.
Our guide to the cheapest GLP-1 option covers the value question, and counterfeit weight loss products covers what scarcity produces. You can compare weight loss treatments available in Pakistan in one place.
The summary
Peptide manufacturing capacity cannot be expanded quickly, and pen assembly is a second bottleneck.
Expanding indications keep adding demand to constrained supply.
Pakistan has no registered standing, so it is served last during shortages and first to run dry.
Exchange rate movement pushes prices up independently of scarcity.
Shortage causes counterfeiting rather than existing alongside it.
Small-molecule oral drugs and patent expiry may eventually change this. Neither helps this month.
Check availability and cash-on-delivery options for something that does not depend on an import shipment.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.